does acalabrutinib increase the risk of hypertension in patients with cll?
Published 7 months ago • 117 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
3:37
identifying patients with cll at a high risk of developing cardiotoxicity with btk inhibitors
-
1:25
hypertension prevalence in cll and how it is affected by acalabrutinib treatment
-
1:15
the current role of acalabrutinib in the treatment of cll
-
2:29
the long-term efficacy of acalabrutinib-based regimens in patients with cll
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
8:57
outcomes of sct in t-all and t-lbl
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
3:27
the safety and efficacy of acalabrutinib for the treatment of r/r mzl
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
2:31
the value of btk inhibitors in cll & the future of acalabrutinib in this disease
-
2:54
the definition of high-risk cll
-
1:26
common side-effects of btk inhibitors (ibrutinib and acalabrutinib) in the treatment of cll
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:58
adding acalabrutinib to the arsenal: impact of ascend in cll
-
0:48
advances in non-covalent btk inhibitors for cll: bruin study update
-
1:13
the importance of improving the management of cardiotoxicity when treating cll